On Tuesday, Ocular Therapeutix Inc (NASDAQ: OCUL) opened lower -1.18% from the last session, before settling in for the closing price of $7.62. Price fluctuations for OCUL have ranged from $4.06 to $11.77 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
A company in the Healthcare sector has jumped its sales by 100.53% annually for the last half of the decade. Company’s average yearly earnings per share was noted 0.73% at the time writing. With a float of $133.91 million, this company’s outstanding shares have now reached $157.75 million.
In an organization with 274 employees, it is important to assess its efficiency. In terms of profitability, gross margin is 91.16%, operating margin of -269.83%, and the pretax margin is -303.95%.
Ocular Therapeutix Inc (OCUL) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Ocular Therapeutix Inc is 15.79%, while institutional ownership is 72.52%. The most recent insider transaction that took place on Feb 24 ’25, was worth 147,533. In this transaction an insider of this company sold 21,475 shares at a rate of $6.87, taking the stock ownership to the 3,520,318 shares. Before that another transaction happened on Feb 24 ’25, when Company’s Chief Scientific Officer sold 3,061 for $6.87, making the entire transaction worth $21,029. This insider now owns 265,998 shares in total.
Ocular Therapeutix Inc (OCUL) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.29 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 0.73% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 4.84% during the next five years compared to 8.51% growth over the previous five years of trading.
Ocular Therapeutix Inc (NASDAQ: OCUL) Trading Performance Indicators
Check out the current performance indicators for Ocular Therapeutix Inc (OCUL). In the past quarter, the stock posted a quick ratio of 10.59. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 18.79.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -1.26, a number that is poised to hit -0.29 in the next quarter and is forecasted to reach -1.29 in one year’s time.
Technical Analysis of Ocular Therapeutix Inc (OCUL)
Let’s dig in a bit further. During the last 5-days, its volume was 1.55 million. That was better than the volume of 1.22 million it reported in year-ago period. As of the previous 9 days, the stock’s Stochastic %D was 17.56%. Additionally, its Average True Range was 0.47.
During the past 100 days, Ocular Therapeutix Inc’s (OCUL) raw stochastic average was set at 29.80%, which indicates a significant increase from 29.44% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 67.57% in the past 14 days, which was higher than the 61.59% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $7.57, while its 200-day Moving Average is $8.38. However, in the short run, Ocular Therapeutix Inc’s stock first resistance to watch stands at $7.68. Second resistance stands at $7.83. The third major resistance level sits at $7.97. If the price goes on to break the first support level at $7.39, it is likely to go to the next support level at $7.26. The third support level lies at $7.11 if the price breaches the second support level.
Ocular Therapeutix Inc (NASDAQ: OCUL) Key Stats
There are currently 159,022K shares outstanding in the company with a market cap of 1.20 billion. Presently, the company’s annual sales total 63,720 K according to its annual income of -193,510 K. Last quarter, the company’s sales amounted to 17,080 K and its income totaled -48,390 K.
